X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (95) 95
humans (92) 92
female (91) 91
adult (54) 54
adolescent (36) 36
obstetrics & gynecology (36) 36
middle aged (34) 34
papillomavirus infections - prevention & control (31) 31
human papillomavirus (30) 30
oncology (30) 30
young adult (30) 30
cervical cancer (28) 28
cancer (26) 26
vaccination (26) 26
papillomavirus infections (23) 23
uterine cervical neoplasms - prevention & control (22) 22
women (22) 22
hpv (21) 21
abridged index medicus (20) 20
aged (20) 20
infection (20) 20
papillomavirus infections - epidemiology (20) 20
vaccines (20) 20
intraepithelial neoplasia (18) 18
pregnancy (18) 18
risk factors (18) 18
papillomavirus infections - virology (17) 17
particle vaccine (17) 17
cervical intraepithelial neoplasia (16) 16
follow-up studies (16) 16
uterine cervical neoplasms - virology (16) 16
clinical trials (15) 15
cervical intraepithelial neoplasia - virology (14) 14
immunology (14) 14
lesions (14) 14
medicine, general & internal (14) 14
prevention (14) 14
risk (14) 14
young-women (14) 14
immunization (13) 13
papillomavirus vaccines - administration & dosage (13) 13
papillomavirus vaccines - therapeutic use (13) 13
retrospective studies (13) 13
biopsy (12) 12
double-blind method (12) 12
immunogenicity (12) 12
papillomavirus vaccines - immunology (12) 12
quadrivalent vaccine (12) 12
vaccine (12) 12
prevalence (11) 11
squamous-cell carcinoma (11) 11
analysis (10) 10
cervical intraepithelial neoplasia - prevention & control (10) 10
efficacy (10) 10
infectious diseases (10) 10
prospective studies (10) 10
research (10) 10
vulvar cancer (10) 10
vulvar neoplasms - pathology (10) 10
cervix (9) 9
human papillomavirus recombinant vaccine quadrivalent, types 6, 11, 16, 18 (9) 9
infections (9) 9
internal medicine (9) 9
medicine & public health (9) 9
prognosis (9) 9
uterine cervical neoplasms - epidemiology (9) 9
clinical-trials (8) 8
colposcopy (8) 8
disease (8) 8
incidence (8) 8
male (8) 8
medicine/public health, general (8) 8
papillomavirus vaccines (8) 8
treatment outcome (8) 8
united-states (8) 8
uterine cervical neoplasms - pathology (8) 8
vagina (8) 8
age (7) 7
aged, 80 and over (7) 7
antibodies (7) 7
austria (7) 7
child (7) 7
condylomata acuminata - prevention & control (7) 7
epidemiology (7) 7
genital warts (7) 7
hpv vaccine (7) 7
management (7) 7
medical and health sciences (7) 7
medicin och hälsovetenskap (7) 7
natural-history (7) 7
papillomavirus infections - immunology (7) 7
papillomavirus vaccines - adverse effects (7) 7
papillomaviruses (7) 7
polymerase chain reaction (7) 7
randomized controlled trials as topic (7) 7
womens health (7) 7
adenocarcinoma (6) 6
aged 16-26 years (6) 6
antibodies, viral - blood (6) 6
cervical intraepithelial neoplasia - pathology (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Wiener Klinische Wochenschrift, ISSN 0043-5325, 10/2012, Volume 124, Issue 19-20, p. 733
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 3/2009, Volume 199, Issue 6, pp. 805 - 814
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 8, pp. 711 - 723
Journal Article
Wiener klinische Wochenschrift, 2012, Volume 124, Issue 19-20, pp. 733 - 734
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9574, pp. 1693 - 1702
Journal Article
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10108, pp. 2143 - 2159
Primary analyses of a study in young women aged 16–26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52,... 
WORLDWIDE | MEDICINE, GENERAL & INTERNAL | IMPACT | VLP VACCINE | METAANALYSIS | DISEASES | PARTICLE VACCINE | GENOTYPE ATTRIBUTION | INFECTION | LESIONS | Immunoassay | Follow-Up Studies | Human papillomavirus 6 - immunology | Humans | Uterine Cervical Neoplasms - epidemiology | Antibodies, Viral - blood | Dose-Response Relationship, Drug | Young Adult | Vaccination - methods | Patient Safety | Adult | Female | Immunogenicity, Vaccine - immunology | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - immunology | Double-Blind Method | Papillomavirus Infections - epidemiology | Uterine Cervical Neoplasms - prevention & control | Treatment Outcome | Injections, Intramuscular | Patient Compliance - statistics & numerical data | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - administration & dosage | Papillomavirus Infections - prevention & control | Adolescent | Primary Prevention - methods | Uterine Cervical Neoplasms - virology | Papillomaviruses | Clinical trials | Vaccines | Papillomavirus infections | Analysis | Women | Human papillomavirus | Immunization | Immunogenicity | Womens health | Epidemiology | Adenocarcinoma | Slopes | Adjudication | Vaccination | Cytology | Infections | Incidence | Randomization | Histopathology | Motivation | Cervical carcinoma | Safety | Lesions | Deoxyribonucleic acid--DNA | Evaluation | Effectiveness | Invasiveness | Abnormalities | Vagina | Cervix | Biopsy | Cervical cancer | Sexual partners | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
BMJ, ISSN 0959-8138, 3/2012, Volume 344, Issue 7851, pp. 16 - 16
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 3/2010, Volume 102, Issue 5, pp. 325 - 339
Background The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital... 
AGED 16-26 YEARS | QUADRIVALENT VACCINE | ONCOLOGY | NEUTRALIZING EPITOPES | CLINICAL-TRIALS | DOUBLE-BLIND | TYPE-18 | VIRUS-LIKE PARTICLES | PROPHYLACTIC EFFICACY | RANDOMIZED CONTROLLED-TRIAL | CERVICAL INTRAEPITHELIAL NEOPLASIA | Human papillomavirus 18 - immunology | Human papillomavirus 6 - immunology | Tumor Virus Infections - virology | Humans | Uterine Cervical Neoplasms - epidemiology | Genital Diseases, Female - prevention & control | Sexually Transmitted Diseases - epidemiology | Alphapapillomavirus - immunology | Human papillomavirus 16 - immunology | Sexually Transmitted Diseases - prevention & control | Young Adult | Adult | Female | Papillomavirus Infections - virology | Cervical Intraepithelial Neoplasia - epidemiology | Human papillomavirus 11 - immunology | Tumor Virus Infections - epidemiology | Papillomavirus Vaccines - administration & dosage | Genital Diseases, Female - virology | Papillomavirus Infections - complications | Global Health | Papanicolaou Test | Sexually Transmitted Diseases - virology | Papillomavirus Infections - epidemiology | Kaplan-Meier Estimate | Uterine Cervical Neoplasms - prevention & control | Vaginal Smears | Papillomavirus Vaccines - pharmacology | Tumor Virus Infections - prevention & control | Cervical Intraepithelial Neoplasia - virology | Tumor Virus Infections - complications | Papillomavirus Infections - prevention & control | Adolescent | Cervical Intraepithelial Neoplasia - prevention & control | Uterine Cervical Neoplasms - virology | Sexual Partners | Prevention | Complications and side effects | Care and treatment | Young women | Research | Health aspects | Papillomavirus infections | Risk factors | Genital diseases, Female | Women | Studies | Human papillomavirus | Immunization | Teenagers | Vaccines | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
BMJ: British Medical Journal, ISSN 0959-8138, 5/2012, Volume 344, Issue 7856, pp. 29 - 30
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2013, Volume 132, Issue 4, pp. 854 - 867
Journal Article
European Journal of Cancer, ISSN 0959-8049, 07/2019, Volume 116, pp. 21 - 26
Vaccines against human papillomavirus (HPV) are available in Europe since 2006. They have been highly effective in preventing infection and disease caused by... 
Prevention | Vaccination | Cervical intraepithelial neoplasia | CIN | Immunity | Cervical cancer | HPV | COST-EFFECTIVENESS | ATTRIBUTION | EFFICACY | WOMEN | IMPACT | ONCOLOGY | HPV VACCINE | INFECTION | BIVALENT | PROGRAM | Papillomaviruses | Colposcopy | Diagnosis | Cancer | Women | Adolescence | Immunization | Young adults | Invasiveness | Medical treatment | Infections | Vaccines | Cervix | Screening | Human papillomavirus | Womens health | Human papilloma viruses | Men | Children | Adolescents | Age
Journal Article
Expert review of pharmacoeconomics & outcomes research, 04/2014, Volume 14, Issue 2, p. 269
The International Agency for Research on Cancer acknowledges that HPV is a human carcinogen affecting both sexes. This study aimed to evaluate the public... 
Quality-Adjusted Life Years | Vaccination - economics | Austria | Public Health | Papillomavirus Infections - prevention & control | Cost-Benefit Analysis | Humans | Female | Male | Papillomavirus Vaccines - immunology | Child
Journal Article